Raytheon awarded $71 million in Navy contracts for missile systems
LONDON and NEW YORK - Renalytix plc (LSE: RENX) (OTCQB: RNLXY), a company specializing in the commercialization of kidneyintelX.dkd, an FDA-approved prognostic test for early-stage chronic kidney disease risk assessment, is set to announce its unaudited interim results for the six months ending December 31, 2024. The results will be released on Tuesday, March 18, 2025.
In conjunction with the release of its financial results, Renalytix will hold two investor presentations to discuss the interim findings. Julian Baines, Executive Chairman of Renalytix, will conduct a live interactive presentation via the Engage Investor platform at 2:00 pm GMT on the same day as the results announcement. The presentation is open to all shareholders and potential investors, who are encouraged to pre-submit questions or pose them during the live event. Interested parties can register for the online event at no cost and access the recording afterward through their personalized investor hub on Engage Investor.
Additionally, an in-person presentation will take place at 5:30 pm GMT on Tuesday, March 25, 2025. This event, also led by Julian Baines, will be held at 75 King William Street, London, and is open to existing and potential shareholders. Attendees are welcome from 5:15 pm, with the presentation commencing at 5:30 pm, followed by refreshments.
These presentations aim to provide shareholders and interested investors with insights into the company’s performance over the past six months and its strategic direction moving forward.
Renalytix’s engagement with its investor base through these events reflects the company’s commitment to transparency and shareholder communication. The presentations are part of Renalytix’s efforts to keep the investment community informed about its progress and developments.
This article is based on a press release statement from Renalytix plc.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.